Daiichi Sankyo Co., Ltd.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2005-09-28
- Employees
- 18.7K
- Market Cap
- -
Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT01181141
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 610
- Registration Number
- NCT01181167
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 716
- Registration Number
- NCT01181102
An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2019-05-23
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 321
- Registration Number
- NCT01040312
- Locations
- 🇯🇵
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan
An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2009-12-25
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 1376
- Registration Number
- NCT01039506
- Locations
- 🇯🇵
Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa-shi, Saitama, Japan
Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-05
- Last Posted Date
- 2010-09-29
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT00914524
Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-10
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT00858702
Late Phase 2 Study of DU-176b in Patients With Non-Valvular Atrial Fibrillation
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 536
- Registration Number
- NCT00829933
DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 234
- Registration Number
- NCT00806624
A Multinational Phase III Study of CS-8958 (MARVEL)
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 1002
- Registration Number
- NCT00803595
© Copyright 2024. All Rights Reserved by MedPath